Astrazeneca

FromAstraZeneca ([email protected])
Subject (44)Enhertu approved in EU for HER2-positive mBC
Preheader (139)Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
Typography
Arial
Colors
Text Analysis
Body Words219
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px752 px
X-Spam Score0.3
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeAfternoon

Enhertu approved in EU for HER2-positive mBC

Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
Enhertu approved in EU for HER2-positive mBC